Our scientific evaluation of and opinions on the EPI-321 publicly available preclinical data
Update: 2025-09-06
Description
"Good morning, and in case I don't see ya, good afternoon, good evening, and good night!" We take our time to evaluate publicly available preclinical data for EPI-321 used to support the Epicrispr Biotechnology first-in-human gene therapy clinical trial for FSHD. We discuss the data in the context of what is known from other neuromuscular disease gene therapy trials and integrate their own data in respect to what metrics are likely needed to be met for have any chance at providing benefit to patients.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
